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Most normal mammalian cells have a finite lifespan1, thought to
constitute a protective mechanism against unlimited prolifer-
ation2–4. This phenomenon, called senescence, is driven by telo-
mere attrition, which triggers the induction of tumour
suppressors including p16INK4a (ref. 5). In cultured cells, senes-
cence can be elicited prematurely by oncogenes6; however, whether
such oncogene-induced senescence represents a physiological
process has long been debated. Human naevi (moles) are benign
tumours of melanocytes that frequently harbour oncogenic
mutations (predominantly V600E, where valine is substituted
for glutamic acid) in BRAF7, a protein kinase and downstream
effector of Ras. Nonetheless, naevi typically remain in a growth-
arrested state for decades and only rarely progress into malig-
nancy (melanoma)8–10. This raises the question of whether naevi
undergo BRAFV600E-induced senescence. Here we show that sus-
tained BRAFV600E expression in human melanocytes induces
cell cycle arrest, which is accompanied by the induction of
both p16INK4a and senescence-associated acidic b-galactosidase
(SA-b-Gal) activity, a commonly used senescence marker. Validat-
ing these results in vivo, congenital naevi are invariably positive
for SA-b-Gal, demonstrating the presence of this classical senes-
cence-associated marker in a largely growth-arrested, neoplastic
human lesion. In growth-arrested melanocytes, both in vitro and
in situ, we observed a marked mosaic induction of p16INK4a,
suggesting that factors other than p16INK4a contribute to protec-
tion against BRAFV600E-driven proliferation. Naevi do not appear
to suffer from telomere attrition, arguing in favour of an
active oncogene-driven senescence process, rather than a loss
of replicative potential. Thus, both in vitro and in vivo,
BRAFV600E-expressing melanocytes display classical hallmarks
of senescence, suggesting that oncogene-induced senescence
represents a genuine protective physiological process.
Melanocytic naevi represent an intriguing human setting where an
activated oncogene can co-exist with long-term arrested cells. Naevi
are very common, clonal and benign tumours of cutaneous mela-
nocytes11, and frequently harbour the V600E mutation in BRAF7
(NCBI gene bank re-named the V599E mutation based on newly
available sequence data; accession number NM_004333.2; hereafter
referred to as BRAFE600). However, in spite of the oncogenic nature of
this mutation12,13, an initial phase of naevus growth is typically
followed by a near-complete cessation of proliferative activity,
which is maintained for many decades8,9,14. Therefore, it is conceiv-
able that growth arrest of naevi results from oncogene-induced
senescence acting as an effective cellular brake against BRAFE600-
mediated oncogenic signalling.
To test this hypothesis, we first determined the effect of the naevus-
associated BRAFE600 mutant on the proliferative capacity of freshly
isolated normal human skin melanocytes. A bicistronic lentiviral
vector co-expressing BRAFE600 and enhanced green fluorescent
protein (eGFP) (to monitor infection efficiency, typically approxi-
mately 90%; Fig. 1a) was used to transduce melanocytes. Short-term
expression of BRAFE600 (3–7 days) led to enhanced melanocyte
proliferation that was measured by a moderate but reproducible
increase in 5-bromodeoxyuridine (BrdU) incorporation (Fig. 1b and
data not shown). However, this effect was transient—sustained
expression of BRAFE600 resulted in marked cell cycle arrest. In
most (roughly 80%) of the transduced melanocytes, this was associ-
ated with an intense activity of SA-b-Gal, a marker for senescent or
stressed cultured cells as well as for aged tissues in vivo6,15 (Fig. 1c).
The p16INK4a protein is a major tumour suppressor, often highly
expressed in senescent cells in vitro and inactivated in a variety of
human cancers, including 30–70% of melanomas16. We found that
BRAFE600-expressing melanocytes had elevated levels of p16INK4a
(Fig. 1d). Notably, the staining for p16INK4a was heterogeneous, with
25–35% of the BRAFE600-expressing melanocytes showing low or
undetectable p16INK4a levels, in spite of the fact that over 95%of these
cells were arrested (and still expressed the lentiviral cassette, as
evident from eGFP expression).
As oncogene-induced senescence in vitro has been best defined in
primary diploid fibroblasts, we analysed the cellular response to
activated BRAF in this ‘reference’ context. Consistent with previous
results obtained with overexpression of RasV12 or Raf1 (refs 6, 17, 18),
retroviral delivery of BRAFE600 into two different strains of normal
human fibroblasts caused a complete cessation of proliferation, along
with induction of p16INK4a (see Supplementary Fig. 1a, b). To exclude
the possibility that these effects were caused by supra-physiological
levels of BRAFE600 expression, we designed a system in which its
expression levels could be manipulated with considerable precision.
Cells were transduced with a mixture of retrovirus encoding
a BRAFE600 expression cassette and retrovirus encoding a short
hairpin (sh)RNA targeting both endogenous wild type and ectopic
BRAFE600 (for details, see Fig. 2 legend). This strategy allowed
expression of BRAFE600 to levels similar to those seen in melanoma
cells (see Supplementary Fig. 2a), or to levels close to, or indis-
tinguishable from, endogenous BRAF levels (Fig. 2a, compare lanes 4
and 5).
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The elevation of p16INK4a levels was maintained on progressively
diminishing BRAFE600 levels (see Supplementary Fig. 2a).We did not
see upregulation of p14ARF by BRAFE600 (see Supplementary Fig. 3).
Furthermore, low levels of BRAFE600 caused inhibition of both DNA
replication (see Supplementary Fig. 2b) and cellular proliferation
(Fig. 2b). This arrest was stably maintained, without any significant
escape (see Supplementary Fig. 2c). However, it was bypassed by co-
expression of the SV40 large tumour antigen (see Supplementary
Fig. 2d), arguing against an aphysiological effect and suggesting that
this arrest depends on cellular tumour suppressors. Furthermore, in
the context of fibroblasts defective for p53 and p16INK4a and expres-
sing SV40 small tumour antigen and human telomerase reverse
transcriptase (hTERT), BRAFE600 could efficiently substitute for
RasV12 in the induction of tumours in immunocompromised mice
(see Supplementary Table 1).
Recently, overexpression of RasV12 has been shown to cause
accumulation of senescence-associated heterochromatic foci
(SAHF), concentrated spots of transcriptionally silenced DNA19.
We observed that low levels of BRAFE600 also induced SAHF
(Fig. 2c). This was accompanied by focal accumulation of a specific
heterochromatin-associated histone modification, namely methyl-
ation of lysine 9 of histone H3 (K9M-H3). Together, these results
indicate that low levels of BRAFE600 induce senescence-like cell cycle
arrest in primary human cells.
To investigate whether p16INK4a upregulation constitutes a
protective response to inappropriate mitogenic signalling by
BRAFE600, we created cell lines stably expressing p16INK4a shRNA.
This shRNA was effective, as it suppressed the accumulation of
p16INK4a in various settings (Fig. 2a), caused increased proliferation
Figure 1 | Sustained expression of BRAFE600 induces a senescence-like
arrest in normal humanmelanocytes. a, Infection efficiency is estimated to
be approximately 90% by visualization of eGFP-positive cells. Nuclear
staining by DAPI is shown as an indication of total cell number. b, Impact of
BRAFE600 on melanocyte proliferation measured as the percentage of
positive cells after a 3-h pulse with BrdU. DAPI stain to detect nuclei (top
panel) and BrdU-positive cells (bottom panel). Control melanocytes
remained proliferative and viable. c, SA-b-Gal activity after brief and
sustained BRAFE600 expression. d, Heterogeneous levels of p16INK4a (upper
panels and lower panels, red) in BRAFE600-transduced melanocytes. DAPI
stain is used to detect nuclei (lower panels, blue). Note that at 21 days after
infection, ,1% of the BRAFE600-expressing melanocytes incorporated
BrdU, the vast majority showed positive SA-b-Gal activity, whereas a smaller
proportion of BRAFE600-expressing cells had detectable p16INK4a expression.
Numbers given are representative of three independent experiments.
Figure 2 | Physiological levels of BRAFE600 induce senescence-like arrest in
normal human fibroblasts in a p16INK4a-independent manner. a–c, Human
BJhTERT cells stably expressing either control or p16
INK4a shRNA were
transduced with a mixture of a retrovirus encoding BRAFE600 expression
and puromycin resistance cassettes, and a retrovirus encoding cassettes for a
shRNA targeting both endogenous wild type and ectopic BRAFE600 and
blasticidin resistance (labelled BRAFE600). Pharmacological selection for
both resistance markers was used to create cells that had stably integrated
both the BRAFE600 expression cassette and the shRNA. The latter alone did
not affect proliferative potential (data not shown). As a control, cells were
transduced with p16INK4a-encoding retrovirus. a, Analysis by western
blotting with b-actin used as a loading control. b, Analysis by proliferation
curves. Shown are the results of three independent experiments performed
in duplicate with standard deviations. c, DAPI staining to detect SAHF
(percentage of SAHF-positive cells is indicated in insert) and
immunofluorescence for K9M-H3. Note that whereas p16INK4a shRNA
neutralized senescence induced by ectopic expression of p16INK4a, it failed to
bypass BRAFE600-induced senescence. Even undetectable levels of BRAFE600
(a, compare lanes 4 and 5) were sufficient to induce growth arrest and SAHF,
in the absence of p16INK4a.
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(see Supplementary Fig. 4) and abolished the induction of cell cycle
arrest by overexpressed p16INK4a (Fig. 2b; see also Supplementary
Fig. 2b, c). However, low levels of BRAFE600 inhibited proliferation
and induced SAHF even on p16INK4a depletion (Fig. 2b, c; see also
Supplementary Fig. 2b, c). Identical observations were made for a
p16INK4a binding-deficient cyclin-dependent kinase 4 mutant
(CDK4R24C; see Supplementary Fig. 2e), for a different fibroblast
strain (TIG3; see Supplementary Fig. 2f–h) and for fibroblasts
explanted from a homozygous p16INK4a-deficient ‘Leiden’ patient20
(see Supplementary Fig. 2i–l). These results suggest that, at least in
cultured human fibroblasts, p16INK4a is upregulated in response to
physiological levels of BRAFE600, but is not strictly required for the
induction of cell cycle arrest.
Next, we wished to validate in vivo our observation that BRAFE600
induces senescence-like arrest in vitro. Given the high frequency of
BRAF mutations in both naevi and melanomas7,12, we looked for
hallmarks of senescence in a panel of resection specimens of human
naevi. We first confirmed the presence of the BRAFE600 mutation in
eight specimens of our panel of 23 naevi (see Supplementary Fig. 5).
We then used paraffin-embedded as well as cryosections of normal
human skin and resection specimens of naevi for further analysis.
Virtually all melanocytes within these naevi were growth-arrested, as
judged by negative immunohistochemical staining for the prolifer-
ation marker Ki-67 (Fig. 3a), in agreement with the literature8,9. This
was in contrast to epidermal keratinocytes in the same specimens,
many of which showed proliferative activity.
As expression of BRAFE600 in cultured human melanocytes led to
cell cycle arrest along with induction of SA-b-Gal activity, we
subjected our naevi panel to analysis for this senescence marker.
SA-b-Gal activity has previously been shown to increase in human
epidermis as a function of age15. To avoid detection of age-induced
SA-b-Gal activity, we analysed a panel of congenital naevi obtained
from patients under one year of age. Indeed, all 23 naevi analysed
displayed high levels of SA-b-Gal activity (Fig. 3a–c). This activity
was absent from normal skin melanocytes within the same samples
(Fig. 3b, c) and in control samples taken from normal skin (Fig. 3a).
In agreement with previous data21, SA-b-Gal activity was also absent
from freshly isolated, cultured primary humanmelanocytes (Fig. 1c).
Terminally differentiated keratinocytes within the epidermis of the
same samples also did not show SA-b-Gal activity (Fig. 3b, c,
arrowheads), consistent with previous observations made in young
(,39 yr of age) donors15. SA-b-Gal activity was similarly lacking
from the cells of skin adnexa, such as the sweat gland (Fig. 3b, c,
labelled S), and from the dermal mesenchymal cells between the
naevus cell nests. Thus, human naevi, largely growth-arrested neo-
plastic lesions, are positive for the senescence marker SA-b-Gal.
Studies in mouse models and humans indicate that (epi)genetic
inactivation of the p16INK4a gene is associated with melanomagen-
esis9,16,22,23. Normal melanocytes, scattered alongside the dermal–
epidermal junction and surrounded by keratinocytes, had undetect-
able levels of p16INK4a (Fig. 3a). In contrast, naevi invariably con-
tained p16INK4a-expressing cells, in agreement with previous
observations9,22. Of note, we failed to detect any significant upregula-
tion of p53 and p21CIP1 in naevi (data not shown). Irrespective of the
mutational status of BRAF in the naevi, the percentage of p16INK4a-
positive cells and the intensity of staining per cell was heterogeneous,
with a striking mosaic pattern of p16INK4a immunopositivity seen in
most naevi (Fig. 3a; see also Supplementary Fig. 6; data not shown).
Figure 3 | Human melanocytic naevi display the hallmarks of senescent
cells. Paraffin-embedded sections of human naevi and normal skin were
subjected to immunohistochemistry with the indicated antibodies. a, Melan
A (brown) identifies melanocytes, MIB1 (brown) recognizes the
proliferationmarker Ki-67 and p16INK4a antibody (brown) detects p16INK4a.
a–c, Frozen sections of human naevi were subjected to SA-b-Gal staining.
The blue staining corresponds exactly to the sites of naevus cell nests. All
cells of the epidermis (mostly keratinocytes, arrowheads) and sweat gland
(S), as well as dermal cells between the naevus cell nests, are completely
negative for SA-b-Gal (b and c). Note that the brown staining in these
samples comes from pigment released by the naevus cells. Where indicated,
haematoxylin and eosin (HE) was used as a counter stain on the consecutive
(SA-b-Gal-stained) section to visualize the melanocyte lesions, within the
context of the surrounding tissue.
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Importantly, all melanocytes within these p16INK4a-mosaic naevi
(whether positive or negative for p16INK4a) were growth arrested
(Fig. 3a; see also Supplementary Fig. 6). Indeed, the lack of pro-
liferation of the naevus melanocytes was associated with positive
SA-b-Gal staining rather than with p16INK4a immunoreactivity,
thereby closely mimicking BRAFE600-expressing melanocytes in vitro.
As naevi are thought to be clonal11, it is unlikely that a differential
BRAF mutation pattern underlies the p16INK4a mosaicism. The
observed p16INK4a mosaicism is in accordance with the occurrence
of growth arrest in naevi of homozygous p16INK4a-deficient Leiden
patients20. However, the naevi of these patients are increased in
number and size compared to those of p16INK4a-proficient indi-
viduals. Together with themosaic p16INK4a pattern seen in BRAFE600-
expressing, growth-arrested melanocytes in vitro, these observations
suggest that p16INK4a collaborates with other, yet-to-be-identified
factors in the establishment of long-term growth arrest of naevi.
Whether p16INK4a contributes to an irreversible arrest that, once
established, no longer requires p16INK4a (as has been suggested
previously19,24), or is involved in aspects of melanoma progression
other than oncogene-induced senescence remains to be determined.
Together these results show that human naevi and BRAFE600-
expressing melanocytes share three senescence-associated markers:
stable growth arrest, heterogeneous induction of p16INK4a and SA-b-
Gal activity.
Although these features support oncogene-induced senescence as
the cause for cell cycle arrest of melanocytic naevi, in principle these
senescence markers may have been triggered by telomere attrition,
which might have resulted from the initial expansion of melanocytes.
Indeed, telomere attrition has been previously proposed as a major
factor involved in the cell-cycle arrest of naevi25. This would be
consistent with the clinical observation that congenital naevi (that is,
arising before birth) can cover large areas of the body surface, in
contrast to naevi acquired later in life, which are usually much
smaller. To test this possibility, we performed telomere FISH (fluores-
cent in situ hybridization) on congenital naevus resections. As
expected, melanoma metastases, stained as controls, displayed
much less fluorescence than their surrounding stromal cells, indi-
cating that this method is sufficiently sensitive to detect differences in
telomere length in situ (Fig. 4a, b; see also Supplementary Fig. 7). In
contrast, we did not observe any significant difference in telomere
fluorescence when comparing congenital naevi to surrounding
tissues, in agreement with previous observations made in acquired
and Spitz naevi26. Although we cannot formally rule out the possi-
bility that a single eroded telomeremay have triggered the senescence
response, one would not expect the other telomeres to remain
apparently full length. These results argue in favour of an active
oncogene-driven senescence process, rather than senescence trig-
gered by exhaustion of replicative potential resulting from gross
telomere attrition.
Our observation that BRAFE600 initially stimulates moderate
melanocyte proliferation supports the hypothesis that it contributes
to the initiating events of melanomagenesis. However, our results
suggest that, both in vitro and in vivo, oncogenic BRAF signalling
subsequently leads to a growth-inhibitory response, which is associ-
ated with the known classical hallmarks of senescence (that is, stable
proliferative arrest, an increase in p16INK4a and the induction of SA-
b-Gal activity). Our results therefore provide support for a specu-
lative model previously proposed9,27, in which BRAFE600 cannot fully
transform human melanocytes, but requires additional, cooperating
events for tumour development. Supporting this view, zebrafish
expressing a BRAFE600 transgene develop ‘fish-naevi’, which require
a p53-deficient background to progress to invasivemelanomas28. Our
observations provide evidence of oncogene-induced senescence as a
physiological mechanism in humans limiting the progression of
premalignant lesions.
METHODS
Plasmids. Gene transfer in normal human melanocytes was achieved with two
independent lentiviral vectors (FG12-HA-BRAFE600-eGFP and HIV-CS-CG-
BRAFE600-puro), with comparable phenotypes. pBabe-puro-BRAFE600 was
used to transduce fibroblasts.
The p16INK4a shRNA sequence corresponds to nucleotides 21–41 (GenBank
accession number NM_000077). The BRAF shRNA sequence was previously
described29.
Cell culture, retroviral transduction, cell cycle analysis and proliferation
curves. Normal human melanocytes were isolated from the epidermis of
neonatal foreskins. Briefly, foreskins were incubated overnight in trypsinization
solution (22.5mM HEPES, 7.5mM glucose, 2.25mM KCl, 100mM NaCl,
0.75mM Na2HPO4 and 0.17% trypsin). Dermis and epidermis were separated
by scraping. The epidermal compartment was incubated for 3–4 d in 254CF
medium (Cascade Biologicals) supplemented with 0.1mM CaCl2, 2% fetal
bovine serum and keratinocyte growth supplement (Cascade Biologicals).
Melanocytes were subsequently separated from keratinocytes by differential
trypsinization. Purity of themelanocytic preparations was estimated by standard
immunostaining for HMB-45. For long-term cultures, melanocytes were pro-
pagated in 254CF medium in the presence of 0.2mM CaCl2 and melanocyte
growth supplement (Cascade Biologicals).
BJ cells expressing hTERT (in pBabeHygro) were grown in DMEM/medium
199 (Gibco) in a 4:1 ratio supplemented with 15% fetal bovine serum (PAA
Laboratories), 0.1mM MEM non-essential amino acids (Gibco), 2mM gluta-
mine (Gibco), 100 unitsml21 penicillin and 0.1mgml21 streptomycin.
Lentiviral infections were performed using HEK293T cells as producers of
viral supernatants. The Phoenix packaging cell line was used for the generation
of ecotropic retroviruses, as described30. Amphotropic retroviruses encoding the
Figure 4 | No apparent telomere loss in naevi. a, Frozen sections of human
naevi and melanomas were subjected to telomere FISH (red). A
representative sample is shown; six naevi were analysed (five of which
harboured the BRAFE600mutation). For reference, sectionswere also stained
with theMelan A antibody (detectingmelanocytes in naevus andmelanoma,
green) and DAPI (blue). Note that in the naevus specimen, both the naevus
cells (Melan-A positive) and the stromal compartment (Melan-A negative)
are FISH positive. In contrast, melanoma tumour cells, which conceivably
have undergone telomere attrition, have a much weaker telomere
fluorescence signal than their surrounding stromal cells. The channel
overlay is shown (individual channels are shown in Supplementary Fig. 7).
b, Quantification of the data in a, plotted as relative telomere fluorescence in
six naevi and threemelanomas (both indicated asmelanocytes) compared to
their respective stromal cells (non-melanocytes) with standard deviations.
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ecotropic receptor were generated in HEK293T cells. All infections were carried
out as described30.
BrdU labelling was carried out for 3 h in reduced growth factor conditions.
Proliferation curves were performed as described6,30.
Human tissue samples. Surgical resection specimens of congenital naevi were
obtained from patients in their first year of life. Specimens were fresh frozen and
stored for a period of 2months to 2 years at 270 8C before use.
Analysis of SA-b-galactosidase activity. Tissues were fixed in 4% formaldehyde
for 2 h, washed with 0.2%NP-40, 0.1%Na-deoxycholate, 2mMMgCl2, 100mM
Na2HPO4, pH 6.0 and stained as described
15. Tissues were post-fixed overnight
in 4% formaldehyde and embedded in paraffin. Cultured cells were stained as
described15.
Immunohistochemistry and antibodies. Tissues were fixed in 4% formal-
dehyde overnight and embedded in paraffin. Paraffin sections were deparaffi-
nized, rehydrated, incubated in 0.1mM sodium citrate pH 6.0, washed and
incubated with peroxidase blocking reagent (S2001; DAKO). The tissue was
incubated with the primary antibodies Ab-3 for Melan A (Molecular
Probes), MIB-1 for Ki-67 (DAKO) and Ab-4 (16P04) for p16INK4a (Molecular
Probes). Secondary antibody used was PowerVision þ (DPVB þ 999HRP;
ImmunoLogic). Peroxidase activity was detected with Liquid DAB (K3468;
DAKO).
The antibodies used for western blotting were F-7 for BRAF (sc-5284; Santa
Cruz), JC8 (MS-889; NeoMarkers) for p16INK4a, C-22 for CDK4 (sc-260; Santa
Cruz) and AC-74 for b-actin (A5316; Sigma). The antibodies used for immuno-
fluorescence were anti-trimethyl-histone H3 (Lys 9) (07-442; Upstate) and
554070 (BD Pharmingen) for p16INK4a. DAPI staining was used to visualize
nuclei.
Telomere FISH. Tissue sections were prepared for FISH analysis with the
2 0 -deoxyoligonucleotide N3 0 ! P5 0 phosphoramidate probe: 5 0 -(CCCTAA)3-
TAMRA-3
0
, specific for telomeric sequences. The Melan A antibody Ab-3 was
used and also the DNA staining dye DAPI. Images of fluorescein (FITC),
TAMRA and DAPI fluorescence were acquired on a digital image microscopy
system. The relative telomere length is proportional to the number of hybridized
probes. For quantification, the fluorescence signal was determined (using ImageJ
software) for all individual telomeres within 12 nuclei per specimen, both for
melanocytes (within naevi and melanomas) and for cells within the stromal
compartments of both types of lesion, for six independent naevi and three
independent melanomas. All measurements have been corrected for background
nuclear fluorescence.
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